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Background: The relevance of the cause of kidney disease to prognosis among patients with chronic
kidney disease is uncertain.
Study Design: Observational study.
Settings & Participants: 6,245 nondialysis participants in the Study of Heart and Renal Protection
(SHARP).
Predictor: Baseline cause of kidney disease was categorized into 4 groups: cystic kidney disease, diabetic
nephropathy, glomerulonephritis, and other recorded diagnoses.
Outcomes: End-stage renal disease (ESRD; dialysis or transplantation) and death.
Results: During an average 4.7 years’ follow-up, 2,080 participants progressed to ESRD, including 454 with
cystic kidney disease (23% per year), 378 with glomerulonephritis (10% per year), 309 with diabetic
nephropathy (12% per year), and 939 with other recorded diagnoses (8% per year). By comparison with
patients with cystic kidney disease, other disease groups had substantially lower adjusted risks of ESRD
(relative risks of 0.28 [95% CI, 0.24-0.32], 0.40 [95% CI, 0.34-0.47], and 0.29 [95% CI, 0.25-0.32] for
glomerulonephritis, diabetic nephropathy, and other recorded diagnoses, respectively). Albuminuria and
baseline estimated glomerular filtration rate were associated more weakly with risk of ESRD in patients with
cystic kidney disease than the 3 other diagnostic categories (P for interaction, ,0.001 and 0.01,
respectively). Death before ESRD was uncommon in patients with cystic kidney disease, but was a major
competing risk for participants with diabetic nephropathy, whose adjusted risk of death was 2-fold higher
than that of the cystic kidney disease group (relative risk, 2.35 [95% CI, 1.73-3.18]).
Limitations: Exclusion of patients with prior myocardial infarction or coronary revascularization.
Conclusions: The cause of kidney disease has substantial prognostic implications. Other things being
equal, patients with cystic kidney disease are at much higher risk of ESRD (and much lower risk of death
before ESRD) than other patients. Patients with diabetic nephropathy are at particularly high risk of death prior
to reaching ESRD.
Am J Kidney Dis. 64(1):40-48. ª 2014 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All
rights reserved.
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Cause of Kidney Disease and Prognosis in CKDsigniﬁcance for the risks of progression or death
beyond that mediated by known risk factors (eg,
albuminuria). Previous observational studies have
been limited to assessments of the relevance of the
cause of kidney disease to kidney disease progres-
sion,6-11 whereas little consideration has been given to
its effect on mortality. The largest such study, the
MDRD (Modiﬁcation of Diet in Renal Disease) Study,
demonstrated that polycystic kidney disease resulted in
more rapid progression than other primary kidney
diseases.10,11 However, this study excluded many pa-
tients with diabetic nephropathy,12 now the most
common cause of ESRD.1
The Study of Heart and Renal Protection (SHARP)
was a large randomized trial of the effects of
cholesterol-lowering therapy on clinical outcomes.
Detailed information for the cause of kidney disease,
kidney function, and other risk factors at baseline,
together with kidney function (including the need for
renal replacement therapy) and death (including the
adjudicated cause) during the 5 years of follow-up,
allows the relevance of the cause of kidney disease
to kidney disease progression and the risk of death to
be explored in more detail.
METHODS
Study Overview
The SHARP trial (ClinicalTrials.gov identiﬁer NCT00125593;
ISRCTN.org study number 54137607) investigated the efﬁcacy of
lowering low-density lipoprotein cholesterol levels with simva-
statin (20 mg daily) plus ezetimibe (10 mg daily) in 9,270
participants with CKD (of whom 6,245 were not on dialysis
therapy at study entry).13 The trial methods have been published in
detail elsewhere and are summarized below.13,14 Ethics approval
was obtained from all study sites prior to enrollment.
Recruitment and Eligibility Criteria
Individuals 40 years or older were eligible to participate if
they had CKD with more than one previous measurement of serum
or plasma creatinine of at least 1.7 mg/dL (150 mmol/L) in men
or 1.5 mg/dL (130 mmol/L) in women. Participants with prior
myocardial infarction or coronary revascularization were excluded.
Baseline Assessment
Cause of kidney disease was recorded by trained study clinic
staff prior to randomization (based on the managing physician’s
clinical diagnosis of the predominant cause of kidney disease, ie,
the “primary renal diagnosis”) and subsequently categorized into 1
of 4 groups: glomerulonephritis, diabetic nephropathy, cystic
kidney disease, and a group that included all other recorded di-
agnoses (including hypertension, renovascular disease, pyelone-
phritis, other known diagnoses, or unknown diagnosis). The
grouping of these other recorded diagnoses into a single category
was done on the basis that participants with such diagnoses had
similar characteristics and prognosis (see Tables S1 and S2,
available as online supplementary material).
The presence of prior vascular disease (coronary artery disease
excluding myocardial infarction or revascularization, stroke, or
peripheral arterial disease), diabetes, smoking status, race, and
comedication were based on self-report by participants. At the
randomization visit, blood pressure, height, and weight wereAm J Kidney Dis. 2014;64(1):40-48measured and samples of nonfasting blood and urine were collected
from all participants. Blood samples were cooled, centrifuged, and
separated before being stored locally at240C. Samples then were
shipped on dry ice to the central laboratory in Oxford, where assays
of plasma creatinine and urinary ACR were conducted. Creatinine
and albumin were measured using a Synchron LX20 or DXC800
analyzer (Beckman Coulter). Creatinine was assayed using a kinetic
alkaline picrate method, calibrated using material traceable to Na-
tional Institute of Standards and Technology (NIST) Standard
Reference Material 914a, with a mean expanded uncertainty of
13.4% (7.3% excluding biological variation).
Follow-up
After 6 weeks of placebo run-in, participants were randomly
assigned to receive the main comparison of simvastatin (20 mg)
plus ezetimibe (10 mg) as a single tablet versus matching placebo
versus simvastatin (20 mg) alone in a ratio of 4:4:1, and treatment
allocation was masked using a double-dummy method. After 1
year, patients initially allocated to receive simvastatin alone (and
who were alive and willing to continue) were randomly assigned
to receive simvastatin plus ezetimibe versus placebo. Participants
were seen at 2 and 6 months after randomization and then every 6
months until ﬁnal follow-up, on average 5 years after initial
randomization. At each visit, blood samples were obtained and
creatinine was analyzed in each site’s local laboratory. Information
for all serious adverse events was sought at each visit and further
documentation was collected on events of interest (including
initiation of renal replacement therapy and all deaths) by study
staff. This information was sent to the international coordinating
center for central adjudication, in accordance with prespeciﬁed
deﬁnitions, by trained clinicians who remained blinded to study
treatment allocation.
The 2 main outcomes of interest for these analyses were ESRD
and death, separately. Rate of change in kidney function was
calculated from local hospital creatinine measurements on samples
obtained at the time of study visits (on average, 9 measurements
per patient were available for slope estimation). eGFR was
calculated using the 4-variable MDRD Study equation.15 Sec-
ondary outcomes included the composite outcomes of ESRD or
death and ESRD or doubling of creatinine level.
Statistical Analysis
Baseline characteristics that were identiﬁed as potential risk
factors for ESRD and mortality were age, sex, country, race,
treatment allocation, prior vascular disease, medication, lipid
levels, smoking, blood pressure, body mass index (BMI), phos-
phate level, hemoglobin level, eGFR, and urinary ACR. Standard
Cox regression techniques were used to assess the etiologic rele-
vance of various baseline characteristics to risk.16
In multivariable analyses, lipid levels, blood pressure, BMI,
phosphate level, hemoglobin level, eGFR, and ACR were ﬁtted
as categorical variables (including when necessary a category
for missing values) to allow for any potential nonlinearity in
the risk relationships. The categories used for these variables
are as follows: diastolic blood pressure, ,80, 80-89, 90-99,
and$100 mm Hg; systolic blood pressure,,140, 140-159, 160-179,
and $180 mm Hg; low-density lipoprotein cholesterol, ,97,
$97-,116, and $116 mg/dL (,2.5, $2.5-,3.0, and $3.0 mmol/L);
high-density lipoprotein cholesterol, ,39, $39-,46, and
$46 mg/dL (,1.0, $1.0-,1.2, and $1.2 mmol/L); trigly-
cerides, ,133, $133-,177, and $177 mg/dL (,1.5, $1.5-,2.0,
and $2.0 mmol/L); BMI, ,24, $24-,28, and $28 kg/m2;
phosphate, ,3.7, $3.7-,4.6, and $4.6 mg/dL (,1.2,
$1.2-,1.5, and $1.5 mmol/L); hemoglobin, ,12, $12-,13,
and $13 g/dL; eGFR, ,15, $15-,30, $30-,60, and $60 mL/
min/1.73 m2; and ACR, ,30, $30-,300, and $300 mg/g.41
Haynes et alIn addition, because of the potential for the competing risk of
death before ESRD, cumulative incidence functions were used to
estimate how the risks of ESRD and death prior to ESRD actually
emerged over time.17 Both Cox and, separately, Fine and Gray
proportional hazards regression models were used to estimate the
relevance of cause of kidney disease to the risks of ESRD and
mortality, before and after adjustment for other risk factors.16,18
Adjusted relative risks (RRs; approximated by the hazard ratios
from the Cox models and the subdistribution HRs from the Fine
and Gray models), together with their 95% conﬁdence intervals
(CIs), were estimated for each cause of kidney disease group
relative to the group of participants with cystic kidney disease. In
ﬁgures, these RRs are presented as “ﬂoating absolute risks”, which
ascribes an appropriate variance to the log of the RR in every
group (including the reference group with RR of 1.00), allowing
comparisons to be made between any 2 groups.19 However, in the
text, all quoted RRs comparing speciﬁed groups of participants are
provided with the appropriate “unﬂoated” CI for that direct
comparison.
To assess whether the prognostic relevance of urinary ACR and
eGFR to ESRD risk differed depending on the cause of kidney
disease, models with appropriate interaction terms were ﬁtted. The
proportional hazards assumption was tested through examination
of the Schoenfeld partial residuals. To calculate the annual rate of
change of eGFR for each patient, linear regression was used to
estimate the rate of change in eGFR from local creatinine values
(ignoring measurements after ESRD). The validity of making
such a “linearity” assumption has been assessed previously
and conﬁrmed to be appropriate.20 Since the reliability of such
estimated progression rates is affected strongly by the number of
available creatinine values (with fewer creatinine measurements
resulting in less reliable estimates of the true progression rate),
participants with fewer than 3 follow-up creatinine measurements
were excluded. In addition, participants for whom the mean de-
viation from their own ﬁtted slope was in the top 1% of the dis-
tribution (of mean deviations across all participants) also were
excluded (1,211 [20%] were excluded in total). Mixed models then
were used to assess the amount of variation in progression rate
explained by cause of kidney disease. These models adjusted for
all other characteristics that were identiﬁed as possible risk factors
for kidney disease progression, with the exception of baseline
eGFR (because this was used in the calculation of the progression
rate, which was the response variable in the mixed models).
RESULTS
Of 6,245 SHARP participants who were not on
dialysis therapy at study entry, 5,990 had a recorded
cause of kidney disease: 675 (11%) had cystic kidney
disease, 1,049 (18%) had glomerulonephritis (most
commonly, “glomerulonephritis–not histologically
examined” [253 participants] or immunoglobulin A
nephropathy [229 participants]) and 886 (15%) had
diabetic nephropathy (Table 1). The group of 3,380
participants with other recorded diagnoses included
993 with hypertensive disease, 404 with pyelone-
phritis, 1,197 with other known diagnosis, and 786
with no known cause.
Participants with cystic kidney disease were
younger and had lower eGFRs at study entry than the
other groups (Table 1). Average baseline ACRs in the
cystic kidney disease and combined other recorded
diagnoses groups were broadly similar (102 and
143 mg/g, respectively) but were substantially higher42in the glomerulonephritis (436 mg/g) and diabetic
nephropathy (601 mg/g) groups. Participants with
diabetic nephropathy were more likely to have
prior vascular disease (25%) than participants with
glomerulonephritis (8%), cystic kidney disease (7%),
or other recorded diagnoses (16%) and more often
were of Asian origin (47% vs 24%, 9%, and 22%
respectively).
For the 5,990 participants not on dialysis therapy
at study entry and with a recorded cause of kidney
disease, average follow-up was 4.7 years. The mean
annual change in eGFR was fastest for participants
with cystic kidney disease (23.8 mL/min/1.73 m2 per
year), intermediate for participants with glomerulo-
nephritis (21.9 mL/min/1.73 m2 per year) or diabetic
nephropathy (22.5 mL/min/1.73 m2 per year), and
slowest for participants with other recorded diagnoses
(21.2 mL/min/1.73 m2 per year; Table 2). In the
group of 3,380 participants with other recorded di-
agnoses, mean annual rates of change in eGFR were
broadly similar for each of the main subcategories
(Table S2). Overall, primary kidney disease explained
16% of the variation in rate of change of eGFR not
already explained by other measured prognostic fac-
tors. Sensitivity analysis including all patients in the
calculation of mean annual change in eGFR did not
materially change these estimates.
Overall, 2,080 participants reached ESRD. The
unadjusted annual rate of reaching ESRD was about
twice as high for participants with cystic kidney dis-
ease (23%) than for those with other primary renal
diagnoses (glomerulonephritis, 10%; diabetic ne-
phropathy, 12%; other recorded diagnoses, 8%;
Table 2; Fig 1). By contrast, participants with cystic
kidney disease had the lowest risk of death before
ESRD (1%), participants with glomerulonephritis and
those with other recorded diagnoses had intermediate
risk (3% and 4%, respectively), and those with dia-
betic nephropathy had the highest risk (8%; Table 2;
Fig 2). As a consequence, the overall risk of ESRD or
death (before ESRD) was almost twice as high for
participants with cystic kidney disease (24%) and
diabetic nephropathy (20%) compared with other
primary renal diagnoses (glomerulonephritis, 13%;
other recorded diagnoses, 12%; Table 2; Fig S1).
Figure 3 shows the effect of adjustment for baseline
characteristics on the association between cause of
kidney disease and ESRD. With the reference group
being those having cystic kidney disease, the risk
of ESRD (estimated from a basic model adjusted
for only age, sex, country, race, and randomized
treatment allocation) was only about half as big for
participants with glomerulonephritis or diabetic ne-
phropathy (RRs of 0.44 [95% CI for direct compari-
son, 0.38-0.51] and 0.54 [95% CI, 0.46-0.64],
respectively), whereas the risk for those with otherAm J Kidney Dis. 2014;64(1):40-48
Table 1. Baseline Characteristics by Renal Diagnosis for 5,990 Patients Not Receiving Dialysis at Randomization and With a
Classified Baseline Cause of Kidney Disease
Cystic Kidney
Disease
(n 5 675)
Glomerulonephritis
(n 5 1,049)
Diabetic
Nephropathy
(n 5 886)
Other Recorded
Diagnosesa
(n 5 3,380)
P for Differences
Between Diagnosis
Groups
Age at randomization (y)b 56 6 10 59 6 12 64 6 10 65 6 12 ,0.001
Men 360 (53) 653 (62) 565 (64) 2,130 (63) ,0.001
Prior vascular diseaseb 50 (7) 85 (8) 221 (25) 539 (16) ,0.001
Diabetesb 25 (4) 80 (8) 886 (100) 398 (12) ,0.001
Current smokerb 94 (14) 121 (12) 90 (10) 429 (13) 0.09
Systolic BP (mm Hg)b 1376 18 1366 19 1456 22 1396 21 ,0.001
Diastolic BP (mm Hg)b 84 6 11 81 6 12 76 6 12 80 6 12 ,0.001
Apolipoprotein A1 (mg/dL)b 137.116 26.43 138.476 29.56 130.836 28.20 137.216 29.35 ,0.001
Apolipoprotein B (mg/dL)b 96.106 21.65 102.016 25.81 96.666 27.74 98.636 25.13 ,0.001
Phosphate (mmol/L) 1.306 0.32 1.28 6 0.33 1.32 6 0.35 1.236 0.30 ,0.001
Hemoglobin (g/dL) 12.596 1.53 12.546 1.73 12.046 1.71 12.686 1.70 ,0.001
BMI (kg/m2)b 26.8 6 4.6 26.86 5.2 28.36 6.2 27.4 6 5.4 ,0.001
Race ,0.001
White 597 (88) 763 (73) 435 (49) 2,473 (73)
Black 4 (,1) 3 (,1) 18 (2) 86 (3)
Asian 58 (9) 256 (24) 419 (47) 759 (22)
Other/not specified 16 (2) 27 (3) 14 (2) 62 (2)
Comedicationb
Antiplatelet therapy 61 (9) 147 (14) 276 (31) 704 (21) ,0.001
ACEi or ARB 499 (74) 716 (68) 566 (64) 1,895 (56) ,0.001
b-Blocker 267 (40) 337 (32) 336 (38) 1296 (38) 0.002
Calcium channel blocker 308 (46) 416 (40) 451 (51) 1,460 (43) ,0.001
eGFR (mL/min/1.73 m2)b,c
Mean 22.86 11.1 25.7 6 12.4 27.6 6 14.6 27.26 13.1 ,0.001
,15 193 (30) 225 (22) 170 (20) 593 (18)
$15-,30 277 (43) 417 (41) 362 (42) 1,399 (43)
$30-,60 174 (27) 371 (36) 311 (36) 1,202 (37)
$60 1 (0) 9 (1) 21 (2) 55 (2)
Urinary ACR (mg/g)c
Median 102 [36-265] 436 [138-1,074] 601 [137-2,024] 143 [30-584] ,0.001
,30 126 (20) 92 (9) 91 (11) 744 (25)
$30-,300 354 (57) 310 (32) 208 (26) 1,143 (38)
$300 138 (22) 571 (59) 498 (62) 1,083 (36)
Randomized to
simvastatin 1 ezetimibe
329 (49) 528 (50) 445 (50) 1,696 (50) 0.9
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean6 standard
deviation or median [interquartile range]. There were 6,245 patients not on dialysis therapy at randomization, but 255 had missing
values for renal diagnosis and have been excluded from all further analyses.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin-creatinine ratio; ARB, angiotensin receptor blocker;
BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate.
aThe group of 3,380 participants with “other recorded diagnoses” included 993 with hypertensive disease, 404 with pyelonephritis,
1,197 with other known diagnosis, and 786 with no known cause.
bVariables updated at 1 year for patients originally allocated to simvastatin only who were re–randomly assigned to simvastatin plus
ezetimibe or placebo.
cPercentages exclude participants for whom data were not available for that category.
Cause of Kidney Disease and Prognosis in CKDrecorded diagnoses was nearly two-thirds lower than
that seen in the cystic kidney disease group (RR, 0.37
[95% CI, 0.33-0.42]). Further adjustment for prior
vascular disease, medication, lipid levels, smoking
status, blood pressure, BMI, and eGFR did not change
these estimates much, but subsequent additional
adjustment for urinary ACR resulted in still biggerAm J Kidney Dis. 2014;64(1):40-48RR differences being observed between participants
with cystic kidney disease and participants with other
diagnoses. Considering those having cystic kidney
disease as the reference group, the fully adjusted RRs
for ESRD were 0.28 (95% CI for direct comparison,
0.24-0.32) for participants with glomerulonephritis,
0.40 (95% CI, 0.34-0.47) for those with diabetic43
Table 2. Renal Progression by Renal Diagnosis in 5,990 Patients Not Receiving Dialysis at Randomization and With a Classified
Baseline Cause of Kidney Disease
Cystic Kidney
Disease Glomerulonephritis
Diabetic
Nephropathy
Other Recorded
Diagnoses
No. randomly assigned 675 1,049 886 3,380
Total person-years at risk of ESRD 1,942 3,711 2,536 12,145
Mean annual rate of change in eGFR
(mL/min/1.73 m2 per y)
23.8 6 2.5 21.96 3.6 22.56 4.8 21.26 3.2
Excluded from calculation of mean
annual rate of change in eGFRa
164 (24) 190 (18) 244 (28) 613 (18)
No. of first events
ESRD 454 (23) 378 (10) 309 (12) 939 (8)
Death before ESRD 21 (1) 97 (3) 206 (8) 478 (4)
ESRD or death 475 (24) 475 (13) 514 (20) 1,417 (12)
Any death 57 (3) 154 (4) 315 (12) 687 (6)
Note: Unless otherwise indicated, values given as number (percentage) or mean6 standard deviation.
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
aPatients with fewer than 3 follow-up creatinine measurements or those with “poorly fitting slopes” (see methods) were excluded.
Haynes et alnephropathy, and 0.29 (95% CI, 0.25-0.32) for those
with other recorded diagnoses. Further subdivision of
the group of participants with other recorded causes
showed similar RRs for each subgroup (RRs of 0.29
[95% CI, 0.25-0.35], 0.24 [95% CI, 0.20-0.30], 0.30
[95% CI, 0.26-0.35], and 0.28 [95% CI, 0.24-0.34]
for participants with hypertensive kidney disease,
pyelonephritis, other known cause, and recorded
cause unknown, respectively).
On the whole, RR estimates derived using Fine and
Gray regression models were broadly similar to those
derived from the Cox regression models (Fig 3;
Fig S2). However, differences in ESRD risk between
participants with diabetic nephropathy and those with
cystic kidney disease became more pronounced when0 1
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44based on the Fine and Gray model rather than the Cox
model (fully adjusted RRs for diabetic nephropathy vs
cystic kidney disease were 0.33 [95% CI for direct
comparison, 0.27-0.41] and 0.40 [95% CI, 0.34-0.47],
respectively). This was because death before ESRD
was a strong competing risk for patients with diabetic
nephropathy. As a consequence, the actual rate at
which patients with diabetic nephropathy would be
expected to present with ESRD (as reﬂected by the
Fine and Gray estimate) would be somewhat lower
than would have been the case in the hypothetical
absence of deaths before ESRD (as reﬂected by the
Cox estimates). Thus, the difference in ESRD rates
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Cause of Kidney Disease and Prognosis in CKDﬁndings were observed in a model of associations
between primary kidney disease and mean annual
decrease in eGFR (Table S3) and in analyses excluding
participants with diabetes from the other recorded di-
agnoses group (data not shown).
eGFR was a highly signiﬁcant predictor of the risks
of ESRD for all categories of primary kidney disease,
but there was some evidence that it was relatively less
important in patients with cystic kidney disease (P for0.25 0.5 1 1.5
Relative risk
(95% CI)
Cystic Kidney Disease
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allocation
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Am J Kidney Dis. 2014;64(1):40-48interaction5 0.01; Table 3). The relative effects of
albuminuria on ESRD also varied according to the pri-
mary kidney disease (P for interaction, 0.001). For
patients with cystic kidney disease, the risk of ESRD
was not signiﬁcantly higher in the presence of micro-
albuminuria (ACR of 30-300 mg/g: RR, 1.18; 95% CI,
0.88-1.58) or macroalbuminuria (ACR$ 300 mg/g:
RR, 1.21; 95% CI, 0.87-1.69), whereas the risks of
ESRD were all substantially increased in association0.25 0.5 1 1.5
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Table 3. Effect of ACR and eGFR Group on Progression to ESRD by Cause of Kidney Disease
Cystic Kidney Disease Glomerulonephritis Diabetic Nephropathy Other Recorded Diagnoses
Urinary ACR (mg/g)a
,30 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
$30-,300 1.18 (0.88-1.58) 2.39 (1.03-5.54) 1.64 (0.79-3.41) 1.39 (1.05-1.84)
$300 1.21 (0.87-1.69) 7.26 (3.22-16.36) 5.85 (2.98-11.49) 3.91 (2.99-5.10)
eGFR (mL/min/1.73 m2)b
,15 13.11 (9.13-18.82) 20.41 (13.98-29.79) 20.58 (14.07-30.11) 23.56 (17.95-30.92)
$15-,30 4.81 (3.41-6.80) 4.71 (3.24-6.84) 3.95 (2.74-5.68) 5.13 (3.94-6.68)
$30 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Note: Values shown are relative risk (95% confidence interval).
Abbreviations: ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
aInteractions between albuminuria group and diagnoses of cystic kidney disease, glomerulonephritis, and diabetic nephropathy, after
adjustment for age, sex, country, race, treatment allocation, prior diseases and medication, lipid levels, smoking, blood pressure, body
mass index, phosphate level, hemoglobin level, and eGFR.
bInteractions between eGFR group and diagnoses of cystic kidney disease, glomerulonephritis, and diabetic nephropathy, after
adjustment for age, sex, country, race, treatment allocation, prior diseases and medication, lipid levels, smoking, blood pressure, body
mass index, phosphate level, hemoglobin level, and ACR.
Haynes et alwith macroalbuminuria among patients with other pri-
mary kidney diseases (Table 3). This interaction be-
tween renal diagnosis andACRwas conﬁrmedwhen the
statistically more sensitive annual rate of change of
eGFR was used as the outcome (data not shown).
Although higherACRpredicted a greater annual decline
in eGFR in all diagnoses, the association wasweaker for
patients with cystic kidney disease.
Figure 4 shows the effect of adjustment for baseline
characteristics on the association between cause of
kidney disease and death. Other things being equal,
participants with cystic kidney disease had the lowest
mortality rates. Compared with participants with0.75 1 2 3
Relative risk
(95% CI)
Cystic Kidney Disease
Age, sex, country,
race and treatment
allocation
+ prior vascular
disease and
medication
+ lipids, smoking,
BP, BMI, phosphate
and haemoglobin
+ eGFR
+ albumin:creatinine 
 ratio
1.00 (0.77, 1.31)
1.00 (0.77, 1.31)
1.00 (0.76, 1.31)
1.00 (0.76, 1.31)
1.00 (0.76, 1.31)
0.75 1 2 3
Relative risk
(95% CI)
Glomerulonephritis
1.22 (1.04, 1.43
1.22 (1.04, 1.44
1.29 (1.10, 1.52
1.32 (1.13, 1.56
1.19 (1.01, 1.40
Figure 4. Effect of adjustment for known risk factors on the asso
estimated using Cox regression. Abbreviations: BMI, body mass inde
glomerular filtration rate.
46cystic kidney disease, mortality rates for participants
with diabetic nephropathy were more than twice
as high (fully adjusted RR, 2.35; 95% CI for direct
comparison, 1.73-3.18), mortality rates for participants
with glomerulonephritis were about one-ﬁfth higher
(RR, 1.19; 95% CI, 0.87-1.63), and mortality rates for
participants with other recorded diagnoses were about
two-ﬁfths higher (RR, 1.42; 95% CI, 1.07-1.87).
DISCUSSION
These analyses show that after adjusting for dif-
ferences in prognostic factors, cystic kidney disease
was associated with a 3-fold higher risk of ESRD and)
)
)
)
)
0.75 1 2 3
Relative risk
(95% CI)
Diabetic Nephropathy
2.53 (2.25, 2.85)
2.38 (2.11, 2.69)
2.48 (2.19, 2.81)
2.75 (2.43, 3.12)
2.35 (2.06, 2.67)
0.75 1 2 3
Relative risk
(95% CI)
Other recorded diagnoses
1.37 (1.27, 1.48)
1.30 (1.20, 1.40)
1.41 (1.31, 1.53)
1.49 (1.38, 1.62)
1.42 (1.31, 1.53)
ciation between cause of kidney disease and death at any time,
x; BP, blood pressure; CI, confidence interval; eGFR, estimated
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Cause of Kidney Disease and Prognosis in CKDat least a one-third lower risk of death compared with
other primary kidney diseases. Polycystic kidney
disease, which is the main cystic disease leading to
ESRD, is a tubular disease that progresses due to the
genetically determined inexorable development and
enlargement of cysts that gradually decrease function
of the surrounding renal tissue, and this may explain
why adjustment for known risk factors did not
attenuate the association between cystic kidney dis-
ease and ESRD risk. Albuminuria in particular was
not associated signiﬁcantly with increased risk of
ESRD (and only weakly associated with rate of
decline in eGFR) for patients with cystic kidney dis-
ease, whereas it was a strong predictor of ESRD risk
(and rate of decline in eGFR) for participants with
other (chieﬂy glomerular) primary kidney diseases
(Table 3). By contrast, the lower risk of death in as-
sociation with cystic kidney disease, which remained
after adjustment for prognostic risk factors, is of un-
certain clinical signiﬁcance and plausibly could be
explained by residual confounding (such as unmea-
sured comorbid conditions).
Our analysis also demonstrated clearly that after
adjustment for albuminuria and other known risk
factors, participants in SHARP with glomerulone-
phritis had risks of progression to ESRD similar to
participants with other (noncystic) primary renal di-
agnoses. Similarly, the risk of death for participants
with glomerulonephritis was intermediate between the
diabetic nephropathy group (who were at highest risk)
and the cystic kidney disease group (at lowest risk)
and similar to the group of participants with other
recorded diagnoses.
The difference between the standard Cox model and
Fine and Gray model (which accounts for competing
risks and aims to estimate the prognostic impact of ex-
posures on outcomes)was apparent only for participants
with diabetic nephropathy. Because participants with
diabetic nephropathy were much more likely than other
participants to die before reaching ESRD, the ESRD rate
that would have been observed in this group (other
things being equal and in a population similar to that
recruited into SHARP) would be similar to the rate
observed in other participants without cystic kidney
disease. This is reﬂected by the similar RRs for ESRD
from the Fine and Gray model for participants with
diabetic nephropathy and those with glomerulonephritis
(RRs of 0.33 [95% CI, 0.27-0.41] and 0.32 [95% CI,
0.27-0.38], respectively) compared with participants
with cystic kidney disease, whereas estimated RRs were
signiﬁcantly different in the Cox model (RRs of 0.40
[95% CI, 0.34-0.47] and 0.28 [95% CI, 0.24-0.32],
respectively). In the SHARP population, participants
with diabetic nephropathy had a similar probability of
reaching ESRD or dying beforehand. However, it is
important to recognize that patients with knownAm J Kidney Dis. 2014;64(1):40-48coronary heart disease were excluded in SHARP,
whereas about a quarter of all patients with diabetic
nephropathy have a history of coronary heart dis-
ease.21,22 For this reason, the risks of dying before
reaching ESRD among unselected patients with diabetic
nephropathy are likely to be even greater than observed
inSHARPandprobablywouldbegreater than the risk of
commencing dialysis therapy. Although measures to
delay progression of kidney disease are important, this
ﬁnding emphasizes the importance of vascular risk (the
most common cause of death in this population) man-
agement for such patients.
The SHARP study population was made up of
willing participants selected for inclusion into a ran-
domized trial. Consequently, they are not likely to be
representative of the CKD population as a whole.
However, the estimates of relative differences pre-
sented (at least from the Cox regression models) still
should be generalizable to other populations with
CKD, as supported by the consistency between our
ﬁndings and those from previous, admittedly smaller,
CKD cohorts.11 Nearly all participants in SHARP had
CKD stage 3b or worse, so results may not be
generalizable to less severe stages of CKD, but most
patients followed up in specialist nephrology clinics
have degrees of CKD similar to those of the SHARP
population.
In conclusion, the cause of kidney disease has
substantial prognostic implications that persist when
other prognostic factors are taken into account. Pa-
tients with cystic kidney disease are at much higher
risk of ESRD (and much lower risk of death) than
other patients. By contrast, patients with diabetic ne-
phropathy are at particularly high risk of death before
reaching ESRD.
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